识别特征DNA参考材料的新资源用于药物遗传学 (PGx) 和人类白细胞抗原 (HLA) 测试:基因测试参考材料 (GeT-RM) 程序PGx搜索工具和GeT-RM综合PGx和HLA表
Laura Scheinfeldt1, Dara Kusic1, Andrea Gaedigk2
1Coriell Institute for Medical Research, Camden, New Jersey.
The Journal of molecular diagnostics : JMD
|March 23, 2025
概括
公共可用的DNA参考材料对于遗传测试质量至关重要. 基因测试参考材料计划 (GeT-RM) 已经生成和更新了用于药物遗传学 (PGx) 和人类白细胞抗原 (HLA) 测试的特征DNA样本.
科学领域:
- 临床遗传学 临床遗传学
- 分子诊断学 分子诊断学
- 参考资料 参考资料 参考资料 参考资料
背景情况:
- 实验室需要基因测试验证和质量控制的参考材料.
- 缺乏公开可用的参考材料阻碍了基因测试的发展.
- 基因测试参考材料计划 (GeT-RM) 解决了这一缺口.
研究的目的:
- 为临床遗传测试生成特征化,可再生和公开可用的DNA参考材料.
- 更新和扩展用于药物遗传学 (PGx) 和人类白细胞抗原 (HLA) 测试的基因型信息.
- 为PGx和HLA基因型数据创建可访问的资源.
主要方法:
- 进行了19项研究,其中9项专注于PGx和HLA测试.
- 用全面和敏感的方法重新分析样本,以更新基因型.
- 扩展分析,包括额外的单核酸变体和恒星等位基因.
主要成果:
- 产生了363个特征化,公开可用的DNA样本.
- 在九个GeT-RMPGx或HLA研究中更新了34个基因/位置的共识基因型.
- 建立了GeT-RM整合PGx和HLA表以及GeT-RMPGx搜索工具.
结论:
- GeT-RM计划为PGx和HLA测试提供了必要的,最新的参考材料.
- 新的资源为363个DNA样本提供了整合和可搜索的基因型数据.
- 这些资源支持提高临床遗传测试的准确性和可靠性.
相关概念视频
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


